Landos Biopharma | TalkMarkets | Page 1
No data available
No data available

People who follow this stock (9)

Latest Posts

About This Stock More About This Stock
Landos Biopharma - Investor Like It Better Than Analysts
Article By: Jim Van Meerten
Thursday, March 7, 2024 4:07 AM EDT
Landos Biopharma is a clinical stage biopharmaceutical company focused on the development of first-in-class therapeutics for patients with autoimmune disease.
In this article: LABP
Read
Week In Review: LianBio Acquires Two IBD Candidates In $218 Million Deal
Article By: ChinaBio® Today
Saturday, May 22, 2021 2:05 PM EDT
LianBio, a Princeton-Shanghai company, in-licensed Greater China rights for two inflammatory bowel disease candidates from Landos Biopharma. The $218 million deal includes $18 million upfront and $200 million in milestones.
In this article: BGNE, BNR, MIST, LABP
Read

Latest Tweets for $LABP

No tweets yet!

PARTNER HEADLINES